<DOC>
	<DOCNO>NCT01717131</DOCNO>
	<brief_summary>Data cohort , prospective study one randomize trial ( ASCOG Z0011 ) support hypothesis omission additional axillary dissection case positive sentinel node limited impact overall survival relapse free survival . However , data sufficient enough recommend , standard care , avoid axillary dissection case positive sentinel node . The ASCOG Z0011 trial close end inclusion predefined non inferiority margin find large ( 5 % difference 5 year primary endpoint ) . Prospective randomize trial urgently mandatory omission axillary node dissection become usual practice without sufficient scientific level proof . Indeed , several review , rate omission axillary node dissection case micrometastasis increase ( Bilimoria ) despite strong proof demonstrate . The omission axillary node dissection case positive sentinel node may strong practical impact patient also medical economical aspect : avoid prolonged hospitalisation , secondary morbidity due axillary dissection require secondary care cost , well cost secondary axillary dissection ( 14 25 % case positive sentinel node ) finally shorten surgery duration . The main investigator propose Non Inferiority Randomized Multicenter Phase III Trial Axillary Node Dissection Versus Axillary Node Dissection Case Positive Sentinel Lymph Node Invasive Breast Cancer</brief_summary>
	<brief_title>Axillary Node Dissection Versus Dissection Breast Cancer With Positive Sentinel Lymph Node</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Patient age 18 year , 2 . Patient invasive breast cancer histologically prove cytologically proven fine needle biopsy , 3 . Patient unifocal tumor T0 T1 T2 5 cm ( clinical imagery ) , without previous therapy ( neoadjuvant chemotherapy hormone therapy ) , 4 . Patient clinical N0 status , 5 . Absence clinically detectable metastasis know , 6 Patients conservative surgery sentinel lymph node ( SLN ) technique feasible start term carcinologic , 7 All patient lymph node involvement ( GS+ ) , whatever size metastasis ( macrometastasis , micrometastasis , cellular cluster isolate tumor cell ) , 8 Patient affiliate social security system benefit system , 9 Signed consent participate . 1 . Tumor 5 cm 2 . Indication neoadjuvant therapy chemotherapy hormone therapy 3 . History breast cancer ( ipsilateral , ie recurrence , contralateral breast ) 4 . History invasive cancer past cutaneous cancer correctly treat 5 . Initial metastatic disease know 6 . Presence clinical axillary adenopathy 7 . Contraindication surgical excision 8 . Contraindication SLN technique 9 . Pregnant woman , childbearing potential , lactate woman 10 Patient deprive liberty supervision guardian 11 Impossibility undergo medical examination study geographical , social psychological reason .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Invasive breast cancer</keyword>
</DOC>